RIGEL PHARMACEUTICALS INC Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2011 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Rigel Pharmaceuticals Inc quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2011 to Q4 2023.
  • Rigel Pharmaceuticals Inc Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $339M, a 0.29% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $339M +$980K +0.29% Dec 31, 2023 10-K 2024-03-05
Q4 2022 $338M +$15.3M +4.73% Dec 31, 2022 10-K 2024-03-05
Q4 2021 $322M +$6.63M +2.1% Dec 31, 2021 10-K 2023-03-07
Q4 2020 $316M +$4.1M +1.32% Dec 31, 2020 10-K 2022-03-01
Q4 2019 $312M +$21.6M +7.45% Dec 31, 2019 10-K 2021-03-02
Q4 2018 $290M +$8.39M +2.98% Dec 31, 2018 10-K 2020-02-27
Q4 2017 $282M -$86.7M -23.5% Dec 31, 2017 10-K 2019-02-28
Q4 2016 $368M +$25.9M +7.55% Dec 31, 2016 10-K 2018-03-06
Q4 2015 $343M -$14.2M -3.99% Dec 31, 2015 10-K 2017-03-07
Q4 2014 $357M +$62.6M +21.3% Dec 31, 2014 10-K 2016-03-08
Q4 2013 $294M +$10.8M +3.83% Dec 31, 2013 10-K 2015-03-03
Q4 2012 $283M +$51.7M +22.3% Dec 31, 2012 10-K 2014-03-04
Q4 2011 $232M Dec 31, 2011 10-K 2013-03-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.